

## Original Article

**Running Title:** Dyslipidemia and Hepatocellular Carcinoma

Received: May 13, 2020; Accepted: June 28, 2021

### **Deranged Lipid Profiles and Hepatocellular carcinoma: Clinical Significance and Association**

Ehab Fawzy Abdo Moustafa<sup>\*</sup>, PhD, Elham Ahmed Hassan<sup>\*♦</sup>, MD, Mohamed Mustafa Mahmoud<sup>\*\*</sup>, MSc, Amal A. Mahmoud<sup>\*\*\*</sup>, MD, Mohamed AA Ghaliony<sup>\*</sup>, MD

<sup>\*</sup>*Department of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Egypt*

<sup>\*\*</sup>*Fever Hospital, Ministry of Health, Sohag, Egypt*

<sup>\*\*\*</sup>*Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt*

#### **♦Corresponding Author**

Elham Ahmed Hassan, MD

Department of Gastroenterology and Tropical Medicine,  
Faculty of Medicine, Assiut University, Egypt

Tel: +20-882410285

Fax: +20-882333327

Email: [mam\\_elham75@yahoo.com](mailto:mam_elham75@yahoo.com)

#### **Abstract**

**Background:** The increasing incidence of hepatocellular carcinoma (HCC) is a challenging health problem worldwide with poor prognosis and limited treatment options. The association between metabolic factors and HCC has been documented, however, there is a shortage of data about this association in our locality. Therefore, we aimed to determine the pattern of lipid profile in cirrhotic patients with HCC and investigate the association between dyslipidemia and HCC.

**Method:** In this case-control hospital-based study, serum lipid profile [total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL)] was determined in 100 patients with cirrhosis and 100 patients with cirrhosis and HCC. Multivariate analysis of HCC risk factors was done.

**Results:** Metabolic syndrome, hypertriglyceridemia, hypercholesterolemia, high LDL, and combined dyslipidemia were significantly more frequent in HCC patients than non-HCC patients. Low HDL and dyslipidemia were significantly associated with the late HCC stages and LDL levels were significantly correlated with  $\alpha$ -fetoprotein levels. There was a tendency towards increasing the values of the other lipid parameters in advanced stages. Metabolic syndrome and combined dyslipidemia were associated with HCC risk.

**Conclusion:** Deranged lipid profiles were common in HCC patients. Metabolic syndrome and combined dyslipidemia could be potential risk factors for HCC and may offer a useful strategy for risk stratification; thus, their control can reduce the HCC burden.

**Keywords:** Dyslipidemias, Hepatocellular carcinoma (HCC), Metabolic Syndrome, Risk factors

## **Introduction**

Over the last decade, the global incidence of hepatocellular carcinoma (HCC) has rapidly increased with nearly 782,000 new cases annually.<sup>1</sup> It represents the sixth common cancer and the fourth cause of cancer-related mortality with about 746,000 annual deaths worldwide.<sup>2-4</sup> Although chronic hepatitis B (HBV), chronic hepatitis C (HCV), and alcoholic liver disease are the major risk factors for HCC, they do not fully explain this recent increase in HCC incidence.<sup>5</sup> Recently, several risk factors for HCC have been documented, such as nonalcoholic fatty liver disease, obesity, and diabetes mellitus (DM).<sup>6-8</sup>

Liver has a crucial role in lipid metabolism and transport. In addition, liver is a main source of the majority of plasma apolipoproteins, endogenous lipids and lipoproteins which depend on the integrity of cellular functions of liver. Hence, in severe liver disease, lipid metabolism is profoundly disturbed.<sup>9</sup> Several reports explored the association between aberrant blood lipid profiles (dyslipidemia) and cancer, including HCC. However, there were discrepancies in these reports, which may be due to the types of cancer or the related confounding factors, including lifestyle, diabetes, and obesity. In regard to HCC, the observed association with dyslipidemia remains elusive and inconsistencies, such as positive or inverse association were found in various studies.<sup>10-12</sup>

In Egypt, HCC is the fourth prevalent cancer where the number of HCC patients increased twofold over a decade.<sup>13, 14</sup> In addition, the major risk factor for HCC is chronic hepatitis C infection. However, to our knowledge, the data about evaluating dyslipidemia as a potential risk for HCC are lacking in our locality. Therefore, we aimed to determine the pattern of lipid profiles in cirrhotic patients with HCC, to

investigate the association between dyslipidemia and HCC, and to shed more light on this important issue gaining more interest worldwide.

## **Patients and Methods**

### ***Study design***

This case-control, hospital-based study was carried out at Assiut University Hospital; a tertiary care teaching hospital, Assiut, Egypt, from January 2019 to January 2020. The study was approved by the Ethics Committee of Assiut University Hospital and was carried out according to the provisions of the Declaration of Helsinki. The ethical approval code was 17101185. An informed consent was obtained from all the participants prior to enrollment.

### ***Study population***

The study group comprised 200 adult patients with liver cirrhosis divided into two groups, 100 patients with HCC and 100 patients without HCC. All patients met the diagnostic criteria of liver cirrhosis by clinical, laboratory, and imaging findings. Furthermore, severity of liver disease was assessed using Child-Pugh score. The diagnosis of HCC was based on the triphasic computed tomography scan in accordance with the guidelines for the diagnosis and treatment of HCC.<sup>15</sup> The staging of HCC was assessed by the Barcelona Clinic Liver Cancer staging system (BCLC),<sup>16</sup> where stages 0, A, and B were known as early stage and stages C and D were known as late or advanced stage.

The patients consecutively enrolled between January 2019 and January 2020 at the Tropical Medicine and Gastroenterology Department, Assiut University Hospital, Egypt. The patients with the evidence of hepatic metastasis, previous HCC therapy, receiving lipid-lowering drugs, or antiviral drugs for B or C were excluded from the study.

## Methods

At study entry, a thorough medical history and physical examination were taken for data collection, including age, sex, metabolic factors like diabetes, hypertension, lifestyle habits, alcohol consumption, medical history, and other related information.

Waist circumference to determine the central obesity was taken at the end of expiration at the midway point between the lower border of the lowest rib and the iliac crest horizontally. Imaging, including abdominal sonography and multi-slice CT (MSCT) was performed to determine liver and spleen size, ascites, and tumor site, size, number and metastasis.

Following an overnight fast, each patient underwent blood tests containing liver function tests, including albumin, bilirubin, aspartate aminotransferase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP), INR, blood picture, alpha feto-protein (AFP), hepatitis B surface antigen (HBs Ag), antibody to hepatitis C virus (HCV-Ab) and lipid profile, including total cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL).

### Definitions

Central obesity was defined as waist circumference >101.6 cm (40 inches) for males and 88.9 cm (35 inches) for females.<sup>17</sup> Metabolic Syndrome was defined as the presence of at least three of the following conditions: central obesity, dyslipidemia (hypertriglyceridemia and lowered HDL), hypertension, and impaired fasting glucose/DM.<sup>17</sup> Combined dyslipidemia was a disorder of lipoprotein metabolism (lipoprotein deficiency or overproduction). Dyslipidemias may be manifested through the elevation of the total

cholesterol, LDL, triglyceride concentrations, and a decrease in HDL concentration in the blood.<sup>18</sup> Hypercholesterolemia was defined as a serum total cholesterol level  $\geq 240$  mg/dl.<sup>19</sup> Hypertriglyceridemia was defined as a serum triglyceride level  $\geq 150$  mg/dl.<sup>17</sup> High LDL was defined as a serum LDL level >160 mg/dl and >70 mg/dl for DM.<sup>19</sup> Low HDL was defined as serum HDL level <40 for males and <50 mg/dl for females.<sup>17</sup> High VLDL was defined as a serum VLDL level >40 mg/dl.<sup>19</sup>

### Statistical analysis

We carried out statistical analyses using SPSS for windows version 16 (IBM Corp., Armonk, NY, USA). The Shapiro-Wilk test of normality was performed to determine the normality of data. Continuous data was expressed as means  $\pm$  standard deviation (SD) or median and (minimum-maximum) and was compared using Student's t-test or Mann-Whitney U test. Categorical variables were expressed as percentages and compared using chi-squared ( $\chi^2$ ) or Fisher's exact probability test. Spearman coefficient correlation was used to find the correlation. Additionally, significant factors in univariate analysis were considered for inclusion in multiple regression analysis to determine risk factors for the development of HCC. For all analyses,  $P < 0.05$  was statistically significant.

## Results

### Characteristics of the studied patients

Two hundred patients with liver cirrhosis (100 with HCC and 100 without HCC) were included in the study. Their mean age was  $62.3 \pm 5$  years and male sex was predominant (70.5%). Most patients had HCV-related cirrhosis (71.5%). None of those patients were alcoholic or had concomitant NASH. Metabolic syndrome was present in 35% of

cirrhotic patients, where its individual components; diabetes mellitus, hypertension, dyslipidemia, and obesity, were present in 42, 51, 37, and 42.5%, respectively. Concerning the lipid profile, low HDL was the most common lipid change (59.5%). hypertriglyceridemia and hypercholesterolemia were present in 33% and 16.5%, respectively.

Further clinical and laboratory data of the studied patients and their subgroups were summarized in table 1.

**Determination of risk factors for HCC**  
Compared with non-HCC group, AFP, AST, and ALT levels were significantly higher in patients with HCC ( $P < 0.001$ ,  $P = 0.02$  and  $P = 0.03$ , respectively). Moreover, univariate analysis indicated that metabolic syndrome ( $P = 0.044$ ), hypercholesterolemia ( $P < 0.001$ ), high LDL ( $P < 0.001$ ), and combined dyslipidemia ( $P = 0.04$ ) were significantly associated with HCC risk in cirrhotic patients as shown in table 1.

In the multivariate analysis, AFP ( $P = 0.001$ ), combined dyslipidemia ( $P = 0.041$ ), and metabolic syndrome ( $P = 0.05$ ) were independent predictors of HCC development in cirrhotic patients. There were no statistically significant differences between both groups regarding other lipid parameters in spite of a tendency towards increased values in cirrhotic patients with HCC (Table 2).

In regard to metabolic risk factors and lipid profile in patients with HBV- and HCV-related HCC, hypertriglyceridemia was significantly more frequent in patients with HCV-related HCC ( $P = 0.018$ ). However, no statistically significant differences were found between both groups regarding metabolic factors and other lipid parameters (Table 3).

### ***Association between dyslipidemia and characteristics of patients with HCC***

Table 4 represents the characteristics of the studied patients with HCC based on the presence of combined dyslipidemia. We noticed that late HCC stages were significantly associated with combined dyslipidemia ( $P = 0.042$ ). Regarding demographic, clinical and the other HCC characteristics, no statistically significant differences were found between the two groups ( $P > 0.05$ ).

In patients with HCC, serum HDL levels were significantly lower in patients with late HCC than early HCC ( $P = 0.012$ ). However, there were no statistical significant differences between the two groups regarding other lipid parameters despite a tendency towards increasing the values in advanced HCC stages as shown in figure 1. Additionally, serum HDL levels were negatively correlated with tumor number ( $\rho = -0.320$ ,  $P = 0.046$ ). LDL levels were significantly correlated with AFP and ( $\rho = 0.380$ ,  $P = 0.031$ ). However, no significant correlations were found between other lipid parameters and AFP, tumor size, or tumor number as summarized in table 5.

### **Discussion**

This study corroborated metabolic syndrome, hypertriglyceridemia, hypercholesterolemia, combined dyslipidemia, and high LDL as predictors of HCC. The current work elucidated that metabolic syndrome was associated with HCC risk (odds ratio= 1.7, 95% CI, 0.94-3.1). It was significantly more common in HCC patients than non-HCC patients, which was in line with earlier studies.<sup>20-22</sup> Welzel et al.<sup>22</sup> reported that metabolic syndrome was significantly associated with the increased HCC risk (odds ratio= 2.13; 95% CI, 1.96-2.31). Metabolic syndrome can promote liver

carcinogenesis in several ways, including potential direct pro-tumoral actions of insulin-resistance, obesity, and NAFLD.<sup>6-8</sup> Moreover, direct oncologic effects of a low-grade inflammatory response can lead to the loss of tumor suppression genes and the deregulation of several signaling pathways.<sup>23</sup>

Consistence with previous works,<sup>24-27</sup> we found that serum cholesterol levels were significantly higher in HCC patients than non-HCC patients and the highest levels were observed in late HCC stages. Higher levels can be attributed to paraneoplastic hypercholesterolemia, the loss of negative feedback mechanism for cholesterol, and impaired uptake of chylomicron remnants in malignant hepatocytes.<sup>24-28</sup> On the other hand, hypercholesterolemia may be related to malignant biliary obstruction and cholesterol overproduction by undifferentiated HCC cells, where more than 90% of cholesterol is released into the circulation.<sup>26,27,29</sup>

Conversely, several studies reported that HCC patients had low cholesterol levels as tumor cells intake much exogenous cholesterol for cytomembrane synthesis, DNA duplication, and oncogene protein regulation.<sup>30-32</sup>

Unlike previous studies,<sup>30,32</sup> we found that serum LDL levels were significantly higher in HCC than non-HCC patients with a tendency towards increased values in late HCC stages. Our findings can be attributed to the reduced LDL receptors resulting in decreased LDL catabolism and increased LDL production in HCC patients with paraneoplastic hypercholesterolemia.<sup>28,33</sup>

Similar to Alsabti,<sup>25</sup> it was observed that hypertriglyceridemia was more frequent in HCC patients than non-HCC patients but with no statistical significance. In contrast, Motta et al.<sup>30</sup>

reported that serum triglyceride levels decreased by 20-30% in HCC patients. Moreover, some studies revealed that its levels in HCC were not significantly different compared with controls.<sup>32,34</sup> Therefore, these discrepancies in serum triglyceride levels in different studies may be an issue for further investigations.

Herein, while no difference between HCC and non-HCC patients regarding HDL levels was observed, lower levels were significantly associated with advanced HCC. Kanel et al.<sup>35</sup> revealed that patients with primary or metastatic liver cancers had remarkably decreased serum HDL levels due to the reduced biosynthesis in severe hepatocellular dysfunction. Ooi et al.<sup>32</sup> reported that low HDL may reflect the pathologic conditions and the severity of liver diseases.

We found that combined dyslipidemia was significantly higher in HCC patients than non-HCC patients and it was associated with an increased HCC risk of 1.86 (95% CI, 1.18-5.33). These results were concomitant with previous reports indicating the association of dyslipidemia with cancer development and progression.<sup>10-12, 36</sup>

In this study, hypertriglyceridemia was significantly more frequent in the HCV-related than the HBV-related HCC group and other lipid parameters implied trends towards a rise in values in the former one. Several authors assumed that chronic HCV infection was associated with viral steatosis that could be responsible for secondary insulin resistance and systemic inflammation and thus an increased HCC risk.<sup>37,38</sup> Viral steatosis are shown to regress after a viral eradication.<sup>39</sup>

Combined dyslipidemias were positively related with BCLC stages of HCC; the higher the stage, the more frequent the dyslipidemia indicating that cancer cells can up-regulate their lipogenic and lipolytic pathways for

gaining lipids.<sup>40</sup> LDL levels were positively correlated with AFP, and HDL levels were negatively related with the HCC number. Moreover, other lipid parameters showed elevated levels but without statistical significance in advanced stages. These increased levels may be related to paraneoplastic syndrome which is associated with poor prognosis and reduced survival.<sup>26,28</sup> Several studies were in accordance with our findings and several others were not, thus indicating the complex role of dyslipidemia in HCC pathogenesis that warrants further evaluation.

This study had some limitations. It was a small-sized sample, single-center study, however, it was conducted in a tertiary care center where different stages of HCC can be evaluated. It was a case-control study thereby making it difficult to determine whether lipid profile changes were the risk factors or sequelae of HCC and if they were risk factors, it was difficult to verify how the duration of exposure to risk-factors could affect HCC development. Hence, large cohort studies will be emphasized to confirm these findings, to clarify their pathogenic mechanisms, and to assess their levels and impact on the prognosis upon HCC treatment.

In conclusion, metabolic syndrome and deranged lipid profiles were common in cirrhotic patients with HCC, particularly in those with HCV infection. Metabolic syndrome and combined dyslipidemia could be potential risk factors for HCC development in cirrhotic patients, which offer a useful risk-stratification strategy; therefore, their control can reduce the HCC burden.

#### **Conflict of Interest**

None declared.

#### **References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* 2015; 65(2): 87-108. doi: 10.3322/caac.21262.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet.* 2018;391(10127):1301-14. doi: 10.1016/S0140-6736(18)30010-2.
3. Villanueva A. Hepatocellular Carcinoma. *N Engl J Med.* 2019;380(15):1450-62. doi: 10.1056/NEJMra1713263.
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015;136(5):E359-86. doi: 10.1002/ijc.29210.
5. Le GM, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. *World J Hepatol.* 2017;9(21):907-20. doi: 10.4254/wjh.v9.i21.907.
6. Argyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. *J BUON.* 2017;22(1):6-20.
7. Reeves HL, Zaki MYW, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. *Dig Dis Sci.* 2016;61(5):1234-45. doi: 10.1007/s10620-016-4085-6.
8. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis c cirrhosis. *Am J Gastroenterol.* 2016;111(11):1573-80. doi: 10.1038/ajg.2016.330.
9. Lewis GF, Rader DJ. New insights into the regulation of HDL

- metabolism and reverse cholesterol transport. *Circ Res*. 2005;96(12):1221-32. doi: 10.1161/01.RES.0000170946.56981.5c.
10. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. *Int J Clin Lab Res*. 2000;30(3):141-5. doi: 10.1007/s005990070013.
  11. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD, Congia M, et al. Serum lipoproteins and cancer. *Nutr Metab Cardiovasc Dis*. 2009;19(3):218-25. doi: 10.1016/j.numecd.2008.06.002.
  12. Usman H, Rashid R, Ameer F, Iqbal A, Zaid M. Revisiting the dyslipidemia associated with acute leukemia. *Clin Chim Acta*. 2015;444:43-49. doi: 10.1016/j.cca.2015.01.038.
  13. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. *JAMA Oncol*. 2017;3(12):1683-91. doi: 10.1001/jamaoncol.2017.3055.
  14. El Zayadi AR, Badran HM, EMF B, Attia Mel- D, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J Gastroenterol*. 2005;11(33):5193-8. doi: 10.3748/wjg.v11.i33.5193.
  15. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011;53(3):1020-2. doi: 10.1002/hep.24199
  16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol*. 2001;35(3):421-30. doi: 10.1016/s0168-8278(01)00130-1.
  17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). *JAMA*. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
  18. George P, Ludvik B. Lipids and diabetes. *J Clin Basic Cardiol*. 2000;3(3):159-62.
  19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110(2):227-39. doi: 10.1161/01.CIR.0000133317.49796.0 E.
  20. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. *Diabetes Care*. 2012;35(11):2402-11. doi: 10.2337/dc12-0336.
  21. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. *Eur J Cancer*. 2008;44(2):293-7. doi: 10.1016/j.ejca.2007.11.005.
  22. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology*. 2011;54(2):463-71. doi: 10.1002/hep.24397.
  23. Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer

- development. *Pathol Oncol Res.* 2015;21(3):527-34. doi: 10.1007/s12253-015-9913-z.
24. Sohda T, Iwata K, Kitamura Y, Suzuki N, Takeyama Y, Irie M, et al. Reduced expression of low-density lipoprotein receptor in hepatocellular carcinoma with paraneoplastic hypercholesterolemia. *J Gastroenterol Hepatol.* 2008;23(7Pt2):e153-e6. doi: 10.1111/j.1440-1746.2007.05115.x.
25. Alsabti' EAK. Serum Lipids in Hepatoma. *Oncology.* 1979;36(1):11-4. doi: 10.1159/000225310.
26. Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic role and significance of paraneoplastic syndromes in patients with hepatocellular carcinoma. *Am Surg.* 2014;80(2):191-6.
27. Alpert ME, Hutt MSR, Davidson CS. Primary hepatoma in Uganda. A prospective clinical and epidemiologic study of forty six patients. *AM J Med.* 1969;46(5):794-802. doi: 10.1016/0002-9343(69)90030-8.
28. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. *Hepatogastroenterology.* 2002;49(47):1315-9.
29. Ahaneku JE, Olubuyide IO, Taylor GO, Agbedana EO. Abnormal lipid and lipoprotein patterns in liver cirrhosis with and without hepatocellular carcinoma. *J Pak Med Assoc.* 1992;42(11):260-3.
30. Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behavior in patients with hepatocellular carcinoma. *Minerva Med.* 2001;92(5):301-5.
31. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. *Proc Natl Acad Sci (USA).* 1989;86(21):8323-7. doi: 10.1073/pnas.86.21.8323.
32. Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. *Int J Mol Med.* 2005;15(4):655-60.
33. Kita T, Brown MS, Bilheimer DW, Goldstein JL. Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. *Proc Natl Acad Sci (USA).* 1982;79(18):5693-7. doi: 10.1073/pnas.79.18.5693.
34. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. *Lipids Health Dis.* 2006;3;5:4. doi: 10.1186/1476-511X-5-4.
35. Kanel GC, Radvan G, Peters RL. High-density lipoprotein cholesterol and liver disease. *Hepatology.* 1983;3(3):343-8. doi: 10.1002/hep.1840030311.
36. Huang J, Li L, Lian J, Schauer S, Vesely PW, Kratky D, et al. Tumor-induced hyperlipidemia contributes to tumor growth. *Cell Rep.* 2016;15(2):336-48. doi: 10.1016/j.celrep.2016.03.020.
37. Moucari R, Asselah T, Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA, and liver fibrosis. *Gastroenterology.* 2008;134(2):416-23. doi: 10.1053/j.gastro.2007.11.010.
38. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Marquitan G, Drebber U, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. *J Hepatol.* 2009;50(1):140-9. doi: 10.1016/j.jhep.2008.08.023.
39. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres O, Poupon RE, Poupon R. Effect of the interaction between steatosis and

alcohol intake on liver fibrosis progression in chronic hepatitis C. *Am J Gastroenterol.* 2002;97(7):1807-12. doi: 10.1111/j.1572-0241.2002.05793.x.

40. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer.* 2007;7(10):763-77. doi: 10.1038/nrc2222.

Table 1. Characteristics of cirrhotic patients with and without HCC

Variables	Total number of cirrhotics (n= 200)	Cirrhotics with HCC (n= 100)	Cirrhotics without HCC (n= 100)	P-value
Age (year)	62.3 ± 5	62.5 ± 5.4	61.98 ± 4.6	0.437
Sex Male/Female	141/59 (70.5/29.5%)	72/28 (72/28%)	69/31 (69/31%)	0.755
<b>Etiology of cirrhosis</b>				
Hepatitis C virus	143 (71.5%)	72 (72%)	71 (71%)	0.202
Hepatitis B virus	28 (14%)	12 (12%)	16 (16%)	
Co- infections	25 (12.5%)	12 (12%)	13 (13%)	
None B none C	4 (2%)	4 (4%)	0 (0%)	
<b>Systemic hypertension</b>	102 (51%)	36 (36%)	28 (28%)	0.396
<b>Diabetes mellitus</b>	84 (42%)	20 (20%)	26 (26%)	0.310
<b>Central obesity</b>	85 (42.5%)	39 (39%)	46 (46%)	0.317
<b>Metabolic syndrome</b>	70 (35%)	41 (41%)	29 (29%)	0.044
<b>Child-Pugh classification Class A/B/C</b>	117/61/22 (58.5/30.5/11%)	54/32/14 (54/32/14%)	63/29/8 (63/29/8%)	0.290
<b>Bilirubin (mg/dl)</b>	0.98 (0.6–14.6)	0.95 (0.7–14.6)	0.98 (0.6–7.2)	0.377
<b>Albumin (mg/dl)</b>	3.4 ± 0.9	3.4 ± 0.9	3.3 ± 0.9	0.264
<b>AST (U/L)</b>	39.5 (22–1800)	67.5 (22–1800)	37.5 (22–234)	0.019
<b>ALT (U/L)</b>	33 (21–351)	58 (22–351)	43 (21–211)	0.030
<b>ALP (U/L)</b>	3.4 ± 0.9	125 (67–658)	111 (61–467)	0.044
<b>INR</b>	1.2 ± 0.3	1.2 ± 0.3	1.2 ± 0.2	0.923
<b>AFP (ng/ml)</b>	9 (2–8000)	556.5 (3–8000)	5 (2–9)	< 0.001
<b>Hypercholesterolemia</b>	33 (16.5%)	29 (29%)	4 (4%)	< 0.001
<b>Hypertriglyceridemia</b>	66 (33%)	39 (39%)	27 (27%)	0.071
<b>Low HDL</b>	119 (59.5%)	63 (63%)	56 (56%)	0.313
<b>High LDL</b>	36 (18%)	28 (28%)	8 (8%)	< 0.001
<b>High VLDL</b>	31 (15.5%)	16 (16%)	15 (15%)	0.845
<b>Combined dyslipidemia</b>	74 (37%)	44 (44%)	30 (30%)	0.040

Values were presented as mean ± standard deviation or median (range) or frequency (%). *P* < 0.05 was significant.

AFP, alpha feto-protein; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; HDL, high density lipoprotein; INR, international randomized ratio; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein

Table 2. Multivariate analysis of the predictors of hepatocellular carcinoma development in cirrhotic patients

	<b>Odds ratio (95%C)</b>	<b>P-value</b>
<b>Metabolic syndrome</b>	1.70 (0.94 - 3.10)	0.050
<b>AST</b>	1.02 (0.99 - 1.05)	0.163
<b>ALT</b>	0.97 (0.93 - 1.02)	0.294
<b>ALP</b>	0.99 (0.98 - 1.03)	0.145
<b>Hypercholesterolemia</b>	0.97 (0.94 - 1.02)	0.235
<b>High LDL</b>	1.02 (0.98 - 1.06)	0.386
<b>AFP</b>	1.57 (1.25 - 2.02)	0.001
<b>Combined dyslipidemia</b>	1.86 (1.18 - 5.33)	0.041

*P*-value was significant if  $< 0.05$

AFP, alpha feto-protein; ALT, alanine transaminase; AST, aspartate transaminase; HCC, hepatocellular carcinoma; LDL, low-density lipoprotein

Table 3. Comparison between metabolic factors and serum lipid parameters in patients with HCV- and HBV-related hepatocellular carcinoma

<b>Variables</b>	<b>HCV-related cirrhotics with HCC (n= 72)</b>	<b>HBV-related cirrhotics with HCC (n= 12)</b>	<b>P-value</b>
<b>Hypertension</b>	36 (50%)	4 (33.3%)	0.285
<b>Diabetes mellitus</b>	24 (33.3%)	2 (16.7%)	0.248
<b>Central obesity</b>	29 (40.3%)	4 (33.3%)	0.648
<b>Metabolic syndrome</b>	30 (41.7%)	4 (33.3%)	0.586
<b>Hypercholesterolemia</b>	22 (30.6%)	1 (8.3%)	0.110
<b>Hypertriglyceridemia</b>	32 (44.4%)	1 (8.3%)	0.018
<b>Low HDL</b>	45 (62.5%)	7 (58.3%)	0.783
<b>High LDL</b>	22 (30.6%)	1 (8.3%)	0.110
<b>High VLDL</b>	14 (19.4%)	0	0.094
<b>Combined dyslipidemia</b>	34 (47.2%)	3 (25%)	0.151

Values are presented as frequency (%). *P*-value < 0.05 was significant.

HCC, hepatocellular carcinoma; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very-low-density lipoprotein

Table 4. Comparison between demographic and clinical characteristics of cirrhotic patients with hepatocellular carcinoma regarding combined dyslipidemia

Variables	HCC with combined dyslipidemia (n= 44)	HCC without combined dyslipidemia (n= 55)	P-value
Age (year)	61.6 ± 5	63.2 ± 5.7	0.615
Sex			
Male/Female	29/15 (65.9/34.1%)	43/13 (76.8/23.2%)	0.229
Etiology of cirrhosis			
HCV infection	34 (77.3%)	38 (67.9%)	0.543
HBV infection	3 (6.8%)	9 (16.1%)	
Co-infection	5 (11.4%)	7 (12.5%)	
Non B, non C	2 (4.5%)	2 (3.6%)	
Ascites	19 (43.2%)	20 (35.7%)	0.447
Splenomegaly	26 (59.1%)	35 (62.5%)	0.729
Hepatomegaly	11 (25%)	18 (32.1%)	0.435
Child-Pugh classification Class A/B/C	23/26/5 (52.3/36.4/11.4%)	31/16/9 (55.4/28.6/16.1%)	0.637
WBCs (x 10 <sup>6</sup> /ml)	6.4 (1.8 - 21)	6.6 (1.7 - 19.3)	0.819
Hb (g/dl)	11.2 ± 3	11.5 ± 3.3	0.615
Platelets (x 10 <sup>6</sup> /ml)	179.5 (49-417)	130 (46-397)	0.154
Bilirubin (mg/dl)	1 (0.7-7.5)	0.9 (0.7-14.6)	0.604
Albumin (mg/dl)	3.5 ± 0.9	3.3 ± 0.9	0.447
AST (U/L)	40 (24-640)	68 (22-1800)	0.669
ALT (U/L)	33.5 (24-239)	35 (22-351)	0.532
ALP (U/L)	124.5 (67-567)	125.5 (69-658)	0.942
INR	1.2 ± 0.2	1.2 ± 0.3	0.893
AFP (ng/ml)	523 (3-5678)	578 (4-8000)	0.736
BCLC-HCC stages			
Early stages (0, A and B)	21 (47.7%)	38 (67.9%)	0.042
Late stages (C and D)	23 (52.3%)	18 (32.1%)	
Tumor site			
Right lobe/Left lobe/Both lobes	27/10/7 (61.4/22.7/15.9%)	38/10/8 (67.9/17.9/14.3%)	0.781
Tumor number			
Single/More than one	29/15 (65.9/34.1%)	46/10 (82.1/17.9%)	0.063
Tumor size (mm)	12 (2.3-56)	6 (1.5-64)	0.099

Values are presented as mean ± standard deviation or median (range) or frequency (%). *P*-value < 0.05 was significant.

AFP, alpha feto-protein; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BCLC; Barcelona Clinic Liver Cancer staging system; INR, international randomized ratio.

Table 5. Correlation between serum lipid parameters and alpha feto-protein

		<b>Triglyceride</b>	<b>Cholesterol</b>	<b>HDL</b>	<b>LDL</b>	<b>VLDL</b>
<b>AFP</b>	<b>Correlation Coefficient (rho)</b>	0.019	0.130	- 0.052	0.380	0.019
	<b>P</b>	0.791	0.067	0.462	0.031	0.788
<b>Tumor size</b>	<b>Correlation Coefficient (rho)</b>	0.045	0.027	- 0.110	0.046	0.059
	<b>P</b>	0.701	0.818	0.347	0.694	0.616
<b>Tumor number</b>	<b>Correlation Coefficient (rho)</b>	0.165	0.024	- 0.320	0.006	0.149
	<b>P</b>	0.101	0.811	0.046	0.956	0.140

*P*-value < 0.05 was significant.

AFP, alpha feto-protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.




Figure 1. Comparison between BCLC stages of HCC regarding serum lipid profile showed that patients with late HCC had significantly lower serum HDL levels compared to those with early HCC ( $P= 0.012$ ), however no statistically significant differences were found between the two groups regarding other lipid parameters.

$P$ -value  $< 0.05$  was significant.

BCLC; Barcelona Clinic Liver Cancer staging system; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.